NICE gives final thumbs up to ThromboGenics/Alcon's Jetrea
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has given Alcon/ThromboGenics' Jetrea (ocriplasmin) a formal and final nod. Today's new guidance makes Jetrea the first drug to be made available on the National Health Service for patients with vitreomacular traction